“Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data ”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 4, July 2024, p. s405, https://doi.org/10.25251/skin.8.supp.405.